Retention Rate of Acalabrutinib in a Non-interventional Setting

Retention rate of acalabrutinib in a non-interventional setting. This is a prospective, multicentre, non-interventional study to collect real-world data on retention rates of CLL patients prescribed with acalabrutinib in Germany.

Inclusion Criteria:Age ≥ 18 yearsDiagnosis of CLLAbility to understand the study concept and to regularly complete patient questionnaires from physical, mental, and linguistic perspectivesDecision to start therapy with acalabrutinib according to the current SmPC. For previously untreated patients as continuous therapy with or without obinutuzumab. OR For patients with at least one prior CLL therapy as continuous monotherapy.Provision of signed informed consent formExclusion Criteria:Current or planned participation in an interventional clinical trialContraindications to treatment with acalabrutinib according to the current SmPCPregnancy or breast feedingDisease progression on prior BTKi therapyStart of acalabrutinib therapy more than 28 days prior to enrolment